Efficacy and Safety of a 4 Year Combination Therapy of Growth Hormone and Gonadotropin- Releasing Hormone Agonist in Children With a Short Predicted Height. (ZomaTrip)

NCT00840944 Phase 4 UNKNOWN

Estrogens are responsible for the disappearance of growth cartilage in the long bones at the end of the pubertal growth spurt both in boys and in girls. It is therefore hypothesized that stopping pubertal development and hence estrogen production, will prolong and increase the pubertal growth spurt, especially when growth hormone is given concommitantly. Boys in early puberty, with a bone age between 11 and 13 years and a predicted adult height below 163 cm or girls in early puberty with a bone age between 10 and 12 years and a predicted height under 151 cm will be treated with triptorelin 3.75 mg and Zomacton growth hormone for 4 years.

Details

Lead sponsor	Belgian Study Group for Pediatric Endocrinology
Phase	Phase 4
Status	UNKNOWN
Enrolment	44
Start date	2008-01
Completion	2024-04

Conditions

• Idiopathic Short Stature

Interventions

• somatropin
• triptorelin

Primary outcomes

• height — 6 - 8 years
  Difference between predicted height at start of treatment and adult height

Countries

Belgium